Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

By C. Paweletz, Lu Charboneau, V. E. Bichsel, N. Simone, Tina Chen, J. Gillespie, M. Emmert-Buck, M. Roth, E. Petricoin, L. Liotta. Oncogene, 2001

952 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. (2005, background): “To begin to understand prostate cancer progression with a systems perspective, we need to characterize and integrate the molecular components involved (Grubb et al., 2003; Hood et al., 2004; Paweletz et al., 2001; Petricoin et al., 2002).”
Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “In addition to Akt/mTOR signaling, Erk (p42/44) MAPK signaling is also frequently activated in prostate cancer, particularly in advanced disease, and is often coordinately deregulated together with Akt signaling (Abreu-Martin et al. 1999; Gioeli et al. 1999; Paweletz et al. 2001;Malik et al. 2002; T”